Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715876 | 0.97 | MEN1 (0.49) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL4714031 | 0.95 | MEN1 (0.50) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL14072837 | 0.93 | MEN1 (0.44) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL5546508 | 0.91 | MEN1 (0.50) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL5004742 | 0.91 | MEN1 (0.44) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL14072838 | 0.90 | MEN1 (0.44) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL4718024 | 0.90 | MEN1 (0.51) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL5538979 | 0.89 | MEN1 (0.48) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| Gsk-364735 SCHEMBL5545304 | 0.89 | KDM4E (0.53) | MEN1KMT2AL3MBTL1HIF1AKDM4E | |
| SCHEMBL5545906 | 0.89 | MEN1 (0.48) | MEN1KMT2AL3MBTL1HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | MEN1 4822/4885KMT2A 1762/4885L3MBTL1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.